BI-5756 Reduces Graft-Versus-Host Disease Through CB1-Mediated Treg Upregulation
Molecules · 2025
DOI: 10.3390/molecules30173517 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Sena Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA. Hauptthemen laut MEDLINE: Graft vs Host Disease, T-Lymphocytes, Regulatory, Receptor, Cannabinoid, CB1. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Edward P. Evans Center for MDS Developmental Research Program, Siteman Research Program Catalyst Award for the Hematopoietic Development & Malignancy Program, St. Baldrick's Foundation.
Abstract (Originalsprache)
Cannabinoid receptor 1 (CB1) has been implicated in multiple inflammatory diseases by regulating pro-inflammatory mediators or altering immune cell polarization. However, the expression and direct functional role of CB1 in T cells remain largely unexplored. Here, we demonstrate that primary murine T cells express CB1 and that its novel agonist, BI-5756, directly increases the frequencies of regulatory T cells (Tregs) in primary murine pan T cells after activation. In addition, BI-5756 exhibits an in vivo protective effect against graft-versus-host disease (GvHD), an allogeneic T cell-mediated inflammatory complication after allogeneic hematopoietic cell transplantation (allo-HCT), resulting in an improved overall survival with enhanced platelet recovery and reconstitution of bone marrow-derived B and T cells. BI-5756 also directly suppresses tumor cell growth and upregulates MHC I, MHC II, and CD80 on tumor cells, which may subsequently enhance T cell-mediated anti-tumor responses in mixed lymphocyte reaction with A20 cells. The ability of BI-5756 to increase Tregs was significantly abrogated by rimonabant, a potent and selective CB1 antagonist, suggesting that the immunomodulatory effect of BI-5756 is mediated via CB1. In summary, BI-5756, a potent CB1 agonist, increases Tregs while preserving anti-tumor responses in vitro and effectively reduces GvHD in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Oncology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA.
ORCID-Profile: Sena Kim, Sora Lim, Jaebok Choi
Förderung
- Edward P. Evans Center for MDS Developmental Research Program
- Siteman Research Program Catalyst Award for the Hematopoietic Development & Malignancy Program
- St. Baldrick's Foundation
- Gabrielle's Angel Foundation
- Siteman Research Program Catalyst Award for the Hematopoietic Development & Malignancy Program
- St. Baldrick’s Foundation
- GAFCR Medical Research Award
Zitieren
APA
Kim, S., Dania, A. J., Lim, S., & Choi, J. (2025). BI-5756 Reduces Graft-Versus-Host Disease Through CB1-Mediated Treg Upregulation. Molecules. https://doi.org/10.3390/molecules30173517
Vancouver
Kim S, Dania AJ, Lim S, Choi J. BI-5756 Reduces Graft-Versus-Host Disease Through CB1-Mediated Treg Upregulation. Molecules. 2025. doi:10.3390/molecules30173517
BibTeX
@article{Kim2025,
author = {Kim, Sena and Dania, Abdul-Jalil and Lim, Sora and Choi, Jaebok},
title = {BI-5756 Reduces Graft-Versus-Host Disease Through CB1-Mediated Treg Upregulation},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30173517}
}
EUVIMED